CTT’s lead therapeutic product, CTT1403, is a PSMA-targeted 177Lu-labeled agent for prostate cancer that can has superior binding characteristics, long circulation half-life, enhanced tumor uptake and unparalleled anti-tumor efficacy. CTT1403 will specifically deliver the radionuclide, 177Lu, minimizing toxic side effects and more effectively treating metastatic prostate cancer and other tumors where PSMA is expressed. Recognizing the same PSMA target and utilizing the same binding region, CTT1403 and its companion agent, CTT1057, can be used as a theranostic pair to effectively detect and treat PSMA positive tumors.
CTT1403 has strong pre-clinical data, showing markedly increased survival and reduction in tumor growth in animal models growing prostate tumors that express PSMA as shown in the survival curve. Animals treated with control compounds survive 40-58 days, while 90% of animals treated with CTT1403 are alive at day 120 and 8/10 animals are cured at the end of the study. CTT1403 has completed all manufacturing and IND-enabling preclinical pharmacology and early safety studies and an IND was filed with FDA in October, 2018. Clinical trials for CTT1403 are expected to start in early 2019 in men with advanced prostate cancer.
Distinguishing Features of CTT1403
- Radiotherapy agent for prostate cancer with superior binding characteristics, long circulation half-life, enhanced tumor uptake and anti-tumor efficacy
- Recognizes a validated biomarker in a cancer with an unmet need
- Possibility for expansion into other cancers based on PSMA expression in the neovasculature
- Strong patent protection